Moderna Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved their RSV vaccine, mRESVIA® (mRNA-1345), for adults aged 18-59 who are at increased risk for respiratory syncytial virus (RSV) disease. This expands the vaccine's previous approval for adults aged 60 and older, granted in May 2024. The approval is based on results from Moderna's Phase 3 study, which showed the vaccine to be well-tolerated and effective in generating immune responses in the younger at-risk population. Moderna plans to have mRESVIA available for both younger and older adults in the U.S. for the 2025-2026 respiratory virus season.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1039171) on June 12, 2025, and is solely responsible for the information contained therein.